Acute improvement in exacerbating XXXX produced by intravenous administration of @entity2656 .

@entity1 @entity4545 @entity2656 @entity4388 @entity17 @entity1219 @entity1372 @entity5993 @entity14645 @entity2827 @entity15 @entity413
The mode of action of @entity4545 (ACTH) treatment in exacerbating @entity15 was studied by short-term infusions of agents that mimic specific and limited pharmacological actions of ACTH and observing for temporally phase-locked clinical changes. The study was double blinded, and agents were administered while the @entity1 were being treated with a standard course of 10-day intramuscular ACTH therapy (40 U twice daily). Antiedema, @entity14645 , extraadrenal, and @entity1372 -retaining actions were studied using infusions of @entity2656 , @entity4388 , ACTH, and @entity2827 , respectively. Seven of 8 @entity1 receiving placebo infusions (2.5% @entity413 ) showed no significant clinical change and 1 exhibited an equivocal improvement. Five of 9 @entity1 receiving @entity2656 showed definite signs of clinical improvement phase-locked to drug administration, with subsequent gradual reversal to baseline. Similar improvements occurred with infusions of @entity5993 in 5 of 8 @entity1 and of ACTH in 4 of 8 @entity1 . Three of 7 @entity1 given @entity1219 infusion showed possible mild improvements. The results indicate that @entity2656 and @entity5993 induced transient acute improvement in signs at the 95% confidence level in @entity1 with exacerbating @entity15 , with ACTH having a similar effect at the 90% confidence level. These agents mimic some of the known effects of ACTH, which may be important in the therapeutic action of ACTH in @entity15 . A possible role for @entity2656 and high-dose ACTH in the treatment of @entity17 disease warrants further study.
